Zheng et al. demonstrated for the first time in Cu/Zn SOD1 transgenic mouse model of ALS that VEGF delayed diseased symptoms progression and prolonged survival, suggesting the importance of VEGF or related compounds in the treatment of ALS patients [93]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.